Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Logothetis

Showing results (841-850 of 1,104) with videos related to

Pageof 111
Sort By:
European Urology Oncology|August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer PatientsEleni Efstathiou, Mark Titus, Sijin Wen, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
Channels (Austin, Tex.)|August 12, 2008
Protein kinase A modulates PLC-dependent regulation and PIP2-sensitivity of K+ channelsCoeli M B Lopes, Juan I Remon, Alessandra Matavel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in boneEleni Efstathiou, Mark Titus, Dimitra Tsavachidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell ClustersAnders Carlsson, Peter Kuhn, Madelyn S Luttgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancerS M Tu, L C Pagliaro, M E Banks, et al.
Current Medical Research and Opinion|July 27, 2007
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groupsJanet van Adelsberg, Peter Gann, Amy T Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2009
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissuesHong Chen, Chrysoula I Liakou, Ashish Kamat, et al.
Oncogene|August 19, 2007
Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new boneZ G Li, J Yang, E S Vazquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an updateC J Logothetis, D E Johnson, C Chong, et al.
Pageof 111

Showing results (841-850 of 1,104) with videos related to

Sort By:
Pageof 111
European Urology Oncology|August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer PatientsEleni Efstathiou, Mark Titus, Sijin Wen, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
Channels (Austin, Tex.)|August 12, 2008
Protein kinase A modulates PLC-dependent regulation and PIP2-sensitivity of K+ channelsCoeli M B Lopes, Juan I Remon, Alessandra Matavel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in boneEleni Efstathiou, Mark Titus, Dimitra Tsavachidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell ClustersAnders Carlsson, Peter Kuhn, Madelyn S Luttgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancerS M Tu, L C Pagliaro, M E Banks, et al.
Current Medical Research and Opinion|July 27, 2007
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groupsJanet van Adelsberg, Peter Gann, Amy T Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2009
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissuesHong Chen, Chrysoula I Liakou, Ashish Kamat, et al.
Oncogene|August 19, 2007
Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new boneZ G Li, J Yang, E S Vazquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an updateC J Logothetis, D E Johnson, C Chong, et al.
Pageof 111